BRIEF-Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program

Reuters11-06

Nov 6 (Reuters) - Tango Therapeutics Inc :

* TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA AND PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM

* TANGO THERAPEUTICS INC: TNG462 DEMONSTRATED DURABLE CLINICAL ACTIVITY ACROSS MULTIPLE TUMOR TYPES

* TANGO THERAPEUTICS INC: MULTIPLE TNG462 COMBINATION STUDIES PLANNED IN 1H 2025

* TANGO THERAPEUTICS INC: TNG908 ENROLLMENT BEING STOPPED TO FULLY RESOURCE TNG462 AND TNG456

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481670871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481670871","market":"us","top_or_hot":-1,"title":"BRIEF-Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program","media":"Reuters","content":"<html><body><p>Nov 6 (Reuters) - Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA AND PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM</p><p>   * TANGO THERAPEUTICS INC: TNG462 DEMONSTRATED DURABLE CLINICAL ACTIVITY ACROSS MULTIPLE TUMOR TYPES</p><p>   * TANGO THERAPEUTICS INC: MULTIPLE TNG462 COMBINATION STUDIES PLANNED IN 1H 2025</p><p>   * TANGO THERAPEUTICS INC: TNG908 ENROLLMENT BEING STOPPED TO FULLY RESOURCE TNG462 AND TNG456</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 20:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 6 (Reuters) - Tango Therapeutics Inc   :   * TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA AND PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM   * TANGO THERAPEUTICS INC: TNG462 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481670871","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481670871","pubTimestamp":1730894608,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 6  - Tango Therapeutics Inc   :   * TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA AND PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM   * TANGO THERAPEUTICS INC: TNG462 DEMONSTRATED DURABLE CLINICAL ACTIVITY ACROSS MULTIPLE TUMOR TYPES   * TANGO THERAPEUTICS INC: MULTIPLE TNG462 COMBINATION STUDIES PLANNED IN 1H 2025   * TANGO THERAPEUTICS INC: TNG908 ENROLLMENT BEING STOPPED TO FULLY RESOURCE TNG462 AND TNG456Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Tango Therapeutics报告积极的TNG462临床数据并提供PRMT5开发计划的更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TNGX":0.9},"content_text":"Nov 6 (Reuters) - Tango Therapeutics Inc   :   * TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA AND PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM   * TANGO THERAPEUTICS INC: TNG462 DEMONSTRATED DURABLE CLINICAL ACTIVITY ACROSS MULTIPLE TUMOR TYPES   * TANGO THERAPEUTICS INC: MULTIPLE TNG462 COMBINATION STUDIES PLANNED IN 1H 2025   * TANGO THERAPEUTICS INC: TNG908 ENROLLMENT BEING STOPPED TO FULLY RESOURCE TNG462 AND TNG456Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481670871"}